<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?</h1>
  <ul>
<li>The drug generated $801.9 million in global sales in the first half of 2025, representing a staggering 89% year-over-year growth, driven by patient demand.</li>
<li>Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo, and Amvuttra — which together generated $1.14 billion in net product revenues, representing a 47% year-over-year increase i</li>
<li>Building on positive phase II KARDIA data, Alnylam and Roche plan to launch the global phase III ZENITH CV outcomes study by late 2025, enrolling about 11,000 high-risk hypertension patients.</li>
<li>The agreement regarding cemdisiran underwent a modification last year.</li>
<li>Alnylam, in collaboration with Roche, is developing investigational RNAi therapy zilebesiran in a mid-stage study (KARDIA-3) to treat hypertension.</li>
<li>The study will test whether twice-yearly 300 mg doses of zilebesiran can reduce the risk of major adverse cardiovascular events compared to placebo.</li>
<li>Recently, the companies reported encouraging Cohort A results, where a single 300 mg dose of zilebesiran achieved clinically meaningful and sustained reductions in office and ambulatory systolic blood pressure, as well a</li>
</ul>
<p><a href="https://finance.yahoo.com/news/alnys-key-partnerships-pharma-giants-141500157.html">Source</a> · 2025-09-08T14:15:00+00:00</p>
</body>
</html>